JP6353064B2 - Ｎｕｄｔ１５遺伝子内の単一塩基多型マーカーを含むチオプリン誘導白血球減少症の発病危険予測用組成物 - Google Patents
Ｎｕｄｔ１５遺伝子内の単一塩基多型マーカーを含むチオプリン誘導白血球減少症の発病危険予測用組成物 Download PDFInfo
- Publication number
- JP6353064B2 JP6353064B2 JP2016548253A JP2016548253A JP6353064B2 JP 6353064 B2 JP6353064 B2 JP 6353064B2 JP 2016548253 A JP2016548253 A JP 2016548253A JP 2016548253 A JP2016548253 A JP 2016548253A JP 6353064 B2 JP6353064 B2 JP 6353064B2
- Authority
- JP
- Japan
- Prior art keywords
- leukopenia
- thiopurine
- risk
- predicting
- nucleotide
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
- 201000002364 leukopenia Diseases 0.000 title claims description 91
- 231100001022 leukopenia Toxicity 0.000 title claims description 89
- 239000002773 nucleotide Substances 0.000 title claims description 46
- 125000003729 nucleotide group Chemical group 0.000 title claims description 46
- HDBQZGJWHMCXIL-UHFFFAOYSA-N 3,7-dihydropurine-2-thione Chemical compound SC1=NC=C2NC=NC2=N1 HDBQZGJWHMCXIL-UHFFFAOYSA-N 0.000 title claims description 43
- 239000000203 mixture Substances 0.000 title claims description 14
- 239000003550 marker Substances 0.000 title claims description 13
- 101150088817 NUDT15 gene Proteins 0.000 title description 7
- GLVAUDGFNGKCSF-UHFFFAOYSA-N mercaptopurine Chemical compound S=C1NC=NC2=C1NC=N2 GLVAUDGFNGKCSF-UHFFFAOYSA-N 0.000 claims description 38
- 238000000034 method Methods 0.000 claims description 32
- LMEKQMALGUDUQG-UHFFFAOYSA-N azathioprine Chemical compound CN1C=NC([N+]([O-])=O)=C1SC1=NC=NC2=C1NC=N2 LMEKQMALGUDUQG-UHFFFAOYSA-N 0.000 claims description 22
- 229960002170 azathioprine Drugs 0.000 claims description 22
- 229960001428 mercaptopurine Drugs 0.000 claims description 22
- 108700028369 Alleles Proteins 0.000 claims description 19
- 108091033319 polynucleotide Proteins 0.000 claims description 18
- 102000040430 polynucleotide Human genes 0.000 claims description 18
- 239000002157 polynucleotide Substances 0.000 claims description 18
- 208000011231 Crohn disease Diseases 0.000 claims description 13
- 239000000523 sample Substances 0.000 claims description 12
- 108020004414 DNA Proteins 0.000 claims description 9
- 230000000295 complement effect Effects 0.000 claims description 7
- 210000000056 organ Anatomy 0.000 claims description 7
- 238000002054 transplantation Methods 0.000 claims description 7
- 206010009900 Colitis ulcerative Diseases 0.000 claims description 6
- 108091028043 Nucleic acid sequence Proteins 0.000 claims description 6
- 201000006704 Ulcerative Colitis Diseases 0.000 claims description 6
- 208000032839 leukemia Diseases 0.000 claims description 6
- 201000010099 disease Diseases 0.000 claims description 3
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims description 3
- 101000991945 Homo sapiens Nucleotide triphosphate diphosphatase NUDT15 Proteins 0.000 description 31
- 102100030661 Nucleotide triphosphate diphosphatase NUDT15 Human genes 0.000 description 31
- 238000004458 analytical method Methods 0.000 description 24
- 210000004027 cell Anatomy 0.000 description 23
- 102000004377 Thiopurine S-methyltransferases Human genes 0.000 description 15
- 108090000958 Thiopurine S-methyltransferases Proteins 0.000 description 15
- 102200104588 rs116855232 Human genes 0.000 description 13
- 238000009412 basement excavation Methods 0.000 description 11
- 208000022559 Inflammatory bowel disease Diseases 0.000 description 8
- 210000000265 leukocyte Anatomy 0.000 description 8
- 230000035772 mutation Effects 0.000 description 7
- 230000035945 sensitivity Effects 0.000 description 7
- 101000661446 Homo sapiens Succinate-CoA ligase [ADP-forming] subunit beta, mitochondrial Proteins 0.000 description 6
- 102100037811 Succinate-CoA ligase [ADP-forming] subunit beta, mitochondrial Human genes 0.000 description 6
- 235000001014 amino acid Nutrition 0.000 description 6
- 150000001413 amino acids Chemical class 0.000 description 5
- 229940079593 drug Drugs 0.000 description 5
- 239000003814 drug Substances 0.000 description 5
- 108090000672 Annexin A5 Proteins 0.000 description 4
- 102000004121 Annexin A5 Human genes 0.000 description 4
- 206010065553 Bone marrow failure Diseases 0.000 description 4
- 238000001890 transfection Methods 0.000 description 4
- FWMNVWWHGCHHJJ-SKKKGAJSSA-N 4-amino-1-[(2r)-6-amino-2-[[(2r)-2-[[(2r)-2-[[(2r)-2-amino-3-phenylpropanoyl]amino]-3-phenylpropanoyl]amino]-4-methylpentanoyl]amino]hexanoyl]piperidine-4-carboxylic acid Chemical compound C([C@H](C(=O)N[C@H](CC(C)C)C(=O)N[C@H](CCCCN)C(=O)N1CCC(N)(CC1)C(O)=O)NC(=O)[C@H](N)CC=1C=CC=CC=1)C1=CC=CC=C1 FWMNVWWHGCHHJJ-SKKKGAJSSA-N 0.000 description 3
- 102000000412 Annexin Human genes 0.000 description 3
- 108050008874 Annexin Proteins 0.000 description 3
- 239000004475 Arginine Substances 0.000 description 3
- ODKSFYDXXFIFQN-UHFFFAOYSA-N arginine Natural products OC(=O)C(N)CCCNC(N)=N ODKSFYDXXFIFQN-UHFFFAOYSA-N 0.000 description 3
- 239000012148 binding buffer Substances 0.000 description 3
- 230000030833 cell death Effects 0.000 description 3
- 235000018417 cysteine Nutrition 0.000 description 3
- XUJNEKJLAYXESH-UHFFFAOYSA-N cysteine Natural products SCC(N)C(O)=O XUJNEKJLAYXESH-UHFFFAOYSA-N 0.000 description 3
- 125000000151 cysteine group Chemical group N[C@@H](CS)C(=O)* 0.000 description 3
- 230000000694 effects Effects 0.000 description 3
- 230000007614 genetic variation Effects 0.000 description 3
- HNDVDQJCIGZPNO-UHFFFAOYSA-N histidine Natural products OC(=O)C(N)CC1=CN=CN1 HNDVDQJCIGZPNO-UHFFFAOYSA-N 0.000 description 3
- 238000009396 hybridization Methods 0.000 description 3
- 108020004999 messenger RNA Proteins 0.000 description 3
- 150000007523 nucleic acids Chemical group 0.000 description 3
- 108090000623 proteins and genes Proteins 0.000 description 3
- 102200022420 rs1142345 Human genes 0.000 description 3
- 102200104587 rs147390019 Human genes 0.000 description 3
- 238000010200 validation analysis Methods 0.000 description 3
- 108020003215 DNA Probes Proteins 0.000 description 2
- 239000003298 DNA probe Substances 0.000 description 2
- 102000004190 Enzymes Human genes 0.000 description 2
- 108090000790 Enzymes Proteins 0.000 description 2
- 238000012300 Sequence Analysis Methods 0.000 description 2
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 2
- 125000003275 alpha amino acid group Chemical group 0.000 description 2
- 238000012098 association analyses Methods 0.000 description 2
- 230000022534 cell killing Effects 0.000 description 2
- 230000003013 cytotoxicity Effects 0.000 description 2
- 231100000135 cytotoxicity Toxicity 0.000 description 2
- 230000007423 decrease Effects 0.000 description 2
- 238000002474 experimental method Methods 0.000 description 2
- MHMNJMPURVTYEJ-UHFFFAOYSA-N fluorescein-5-isothiocyanate Chemical compound O1C(=O)C2=CC(N=C=S)=CC=C2C21C1=CC=C(O)C=C1OC1=CC(O)=CC=C21 MHMNJMPURVTYEJ-UHFFFAOYSA-N 0.000 description 2
- 230000002068 genetic effect Effects 0.000 description 2
- 238000007894 restriction fragment length polymorphism technique Methods 0.000 description 2
- 230000004083 survival effect Effects 0.000 description 2
- 238000012360 testing method Methods 0.000 description 2
- 108091032973 (ribonucleotides)n+m Proteins 0.000 description 1
- JKMHFZQWWAIEOD-UHFFFAOYSA-N 2-[4-(2-hydroxyethyl)piperazin-1-yl]ethanesulfonic acid Chemical compound OCC[NH+]1CCN(CCS([O-])(=O)=O)CC1 JKMHFZQWWAIEOD-UHFFFAOYSA-N 0.000 description 1
- 108090000669 Annexin A4 Proteins 0.000 description 1
- 102100034612 Annexin A4 Human genes 0.000 description 1
- 102100027098 CMP-N-acetylneuraminate-beta-galactosamide-alpha-2,3-sialyltransferase 1 Human genes 0.000 description 1
- 238000007400 DNA extraction Methods 0.000 description 1
- 238000000018 DNA microarray Methods 0.000 description 1
- 230000006820 DNA synthesis Effects 0.000 description 1
- 102000016928 DNA-directed DNA polymerase Human genes 0.000 description 1
- 108010014303 DNA-directed DNA polymerase Proteins 0.000 description 1
- 102100031813 Fibulin-2 Human genes 0.000 description 1
- 239000007995 HEPES buffer Substances 0.000 description 1
- 101000836774 Homo sapiens CMP-N-acetylneuraminate-beta-galactosamide-alpha-2,3-sialyltransferase 1 Proteins 0.000 description 1
- 101001065274 Homo sapiens Fibulin-2 Proteins 0.000 description 1
- 101000969961 Homo sapiens Neurexin-3 Proteins 0.000 description 1
- 101000969963 Homo sapiens Neurexin-3-beta Proteins 0.000 description 1
- 101000744394 Homo sapiens Oxidized purine nucleoside triphosphate hydrolase Proteins 0.000 description 1
- 102100034343 Integrase Human genes 0.000 description 1
- 239000012097 Lipofectamine 2000 Substances 0.000 description 1
- 206010028980 Neoplasm Diseases 0.000 description 1
- 102100021310 Neurexin-3 Human genes 0.000 description 1
- 108020005187 Oligonucleotide Probes Proteins 0.000 description 1
- 102100039792 Oxidized purine nucleoside triphosphate hydrolase Human genes 0.000 description 1
- 238000009004 PCR Kit Methods 0.000 description 1
- 108020004518 RNA Probes Proteins 0.000 description 1
- 239000003391 RNA probe Substances 0.000 description 1
- 108010092799 RNA-directed DNA polymerase Proteins 0.000 description 1
- 238000010240 RT-PCR analysis Methods 0.000 description 1
- 238000002105 Southern blotting Methods 0.000 description 1
- 238000000692 Student's t-test Methods 0.000 description 1
- OKKRPWIIYQTPQF-UHFFFAOYSA-N Trimethylolpropane trimethacrylate Chemical compound CC(=C)C(=O)OCC(CC)(COC(=O)C(C)=C)COC(=O)C(C)=C OKKRPWIIYQTPQF-UHFFFAOYSA-N 0.000 description 1
- GLNADSQYFUSGOU-GPTZEZBUSA-J Trypan blue Chemical compound [Na+].[Na+].[Na+].[Na+].C1=C(S([O-])(=O)=O)C=C2C=C(S([O-])(=O)=O)C(/N=N/C3=CC=C(C=C3C)C=3C=C(C(=CC=3)\N=N\C=3C(=CC4=CC(=CC(N)=C4C=3O)S([O-])(=O)=O)S([O-])(=O)=O)C)=C(O)C2=C1N GLNADSQYFUSGOU-GPTZEZBUSA-J 0.000 description 1
- 230000002159 abnormal effect Effects 0.000 description 1
- 230000002411 adverse Effects 0.000 description 1
- 230000003321 amplification Effects 0.000 description 1
- 230000000692 anti-sense effect Effects 0.000 description 1
- 230000006907 apoptotic process Effects 0.000 description 1
- 238000003556 assay Methods 0.000 description 1
- 210000004369 blood Anatomy 0.000 description 1
- 239000008280 blood Substances 0.000 description 1
- 230000037396 body weight Effects 0.000 description 1
- 239000007853 buffer solution Substances 0.000 description 1
- 201000011510 cancer Diseases 0.000 description 1
- 239000003153 chemical reaction reagent Substances 0.000 description 1
- 210000000349 chromosome Anatomy 0.000 description 1
- 238000012937 correction Methods 0.000 description 1
- 231100000433 cytotoxic Toxicity 0.000 description 1
- 230000001472 cytotoxic effect Effects 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- 238000003745 diagnosis Methods 0.000 description 1
- 238000010586 diagram Methods 0.000 description 1
- 238000001839 endoscopy Methods 0.000 description 1
- 238000001943 fluorescence-activated cell sorting Methods 0.000 description 1
- 238000009472 formulation Methods 0.000 description 1
- 125000000487 histidyl group Chemical group [H]N([H])C(C(=O)O*)C([H])([H])C1=C([H])N([H])C([H])=N1 0.000 description 1
- 125000002887 hydroxy group Chemical group [H]O* 0.000 description 1
- 208000026278 immune system disease Diseases 0.000 description 1
- 208000027866 inflammatory disease Diseases 0.000 description 1
- 238000007477 logistic regression Methods 0.000 description 1
- 238000001840 matrix-assisted laser desorption--ionisation time-of-flight mass spectrometry Methods 0.000 description 1
- 238000002844 melting Methods 0.000 description 1
- 230000008018 melting Effects 0.000 description 1
- 238000003199 nucleic acid amplification method Methods 0.000 description 1
- 239000002777 nucleoside Substances 0.000 description 1
- -1 nucleoside triphosphates Chemical class 0.000 description 1
- 239000002751 oligonucleotide probe Substances 0.000 description 1
- 238000006116 polymerization reaction Methods 0.000 description 1
- XJMOSONTPMZWPB-UHFFFAOYSA-M propidium iodide Chemical compound [I-].[I-].C12=CC(N)=CC=C2C2=CC=C(N)C=C2[N+](CCC[N+](C)(CC)CC)=C1C1=CC=CC=C1 XJMOSONTPMZWPB-UHFFFAOYSA-M 0.000 description 1
- 238000012342 propidium iodide staining Methods 0.000 description 1
- 238000012175 pyrosequencing Methods 0.000 description 1
- 238000012552 review Methods 0.000 description 1
- 102200104593 rs186364861 Human genes 0.000 description 1
- 238000005204 segregation Methods 0.000 description 1
- 210000004927 skin cell Anatomy 0.000 description 1
- 239000011780 sodium chloride Substances 0.000 description 1
- 238000010186 staining Methods 0.000 description 1
- 238000013517 stratification Methods 0.000 description 1
- 238000006467 substitution reaction Methods 0.000 description 1
- 239000001226 triphosphate Substances 0.000 description 1
- 235000011178 triphosphate Nutrition 0.000 description 1
- 230000035899 viability Effects 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
- C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
- C12Q1/6888—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for detection or identification of organisms
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q2600/00—Oligonucleotides characterized by their use
- C12Q2600/112—Disease subtyping, staging or classification
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q2600/00—Oligonucleotides characterized by their use
- C12Q2600/156—Polymorphic or mutational markers
Landscapes
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Analytical Chemistry (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Organic Chemistry (AREA)
- Zoology (AREA)
- Wood Science & Technology (AREA)
- Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Microbiology (AREA)
- Immunology (AREA)
- Molecular Biology (AREA)
- Biotechnology (AREA)
- Biophysics (AREA)
- Physics & Mathematics (AREA)
- Biochemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Engineering & Computer Science (AREA)
- General Health & Medical Sciences (AREA)
- Genetics & Genomics (AREA)
- Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| KR10-2014-0007821 | 2014-01-22 | ||
| KR20140007821 | 2014-01-22 | ||
| KR1020140193130A KR101704143B1 (ko) | 2014-01-22 | 2014-12-30 | Nudt15 유전자 내의 단일염기다형성 마커를 포함하는 티오퓨린 유도 백혈구 감소증 발병 위험 예측용 조성물 |
| PCT/KR2014/013050 WO2015111852A1 (ko) | 2014-01-22 | 2014-12-30 | Nudt15 유전자 내의 단일염기다형성 마커를 포함하는 티오퓨린 유도 백혈구 감소증 발병 위험 예측용 조성물 |
| KR10-2014-0193130 | 2014-12-30 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2017503523A JP2017503523A (ja) | 2017-02-02 |
| JP6353064B2 true JP6353064B2 (ja) | 2018-07-04 |
Family
ID=53877285
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2016548253A Active JP6353064B2 (ja) | 2014-01-22 | 2014-12-30 | Ｎｕｄｔ１５遺伝子内の単一塩基多型マーカーを含むチオプリン誘導白血球減少症の発病危険予測用組成物 |
Country Status (3)
| Country | Link |
|---|---|
| JP (1) | JP6353064B2 (zh) |
| KR (1) | KR101704143B1 (zh) |
| CN (1) | CN106536749B (zh) |
Families Citing this family (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN107299137A (zh) * | 2017-07-06 | 2017-10-27 | 广州海思医疗科技有限公司 | 一组高特异性的nudt15引物及探针 |
| CN107574239A (zh) * | 2017-10-25 | 2018-01-12 | 广州和康医疗技术有限公司 | 一种检测硫嘌呤药物snp位点基因型的检测方法及试剂盒 |
| CN107988354B (zh) * | 2017-12-13 | 2021-05-14 | 广州迈景基因医学科技有限公司 | Nudt15基因分型用的引物、试剂盒及方法 |
| KR102304555B1 (ko) | 2018-12-28 | 2021-09-27 | 서울대학교 산학협력단 | 약물 유도 백혈구 감소증 발병 위험 예측용 crim1 유전자 단일염기다형성 마커 및 이를 이용한 백혈구 감소증 발병 위험 예측 방법 |
| WO2020153617A1 (ko) * | 2019-01-25 | 2020-07-30 | 서울대학교 산학협력단 | 약물 유도 백혈구 감소증 발병 위험 예측용 il6 유전자 단일염기다형성 마커 및 이를 이용한 백혈구 감소증 발병 위험 예측 방법 |
| CN114250289A (zh) * | 2021-11-01 | 2022-03-29 | 济南艾迪康医学检验中心有限公司 | 检测NUDT15基因c.37_42dup GGAGTC突变的引物、方法和试剂盒 |
Family Cites Families (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP1961825A1 (en) * | 2007-02-26 | 2008-08-27 | INSERM (Institut National de la Santé et de la Recherche Medicale) | Method for predicting the occurrence of metastasis in breast cancer patients |
| JP6017117B2 (ja) * | 2011-05-02 | 2016-10-26 | 株式会社 ハプロファーマ | 炎症性腸疾患患者におけるアザチオプリン（ａｚｔ）の血中濃度の安定性を予測するジェネティックバイオマーカー |
| KR101369045B1 (ko) * | 2013-10-16 | 2014-03-03 | 울산대학교 산학협력단 | 한국인의 궤양성 대장염 및 크론병 위험 예측용 다형성 마커, 이를 이용한 대장염 또는 크론병 위험 예측 방법 |
-
2014
- 2014-12-30 CN CN201480077384.5A patent/CN106536749B/zh active Active
- 2014-12-30 KR KR1020140193130A patent/KR101704143B1/ko active IP Right Grant
- 2014-12-30 JP JP2016548253A patent/JP6353064B2/ja active Active
Also Published As
| Publication number | Publication date |
|---|---|
| KR20150088175A (ko) | 2015-07-31 |
| JP2017503523A (ja) | 2017-02-02 |
| CN106536749B (zh) | 2020-02-14 |
| KR101704143B1 (ko) | 2017-02-09 |
| CN106536749A (zh) | 2017-03-22 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Stein et al. | A decade of research on the 17q12-21 asthma locus: piecing together the puzzle | |
| JP6353064B2 (ja) | Ｎｕｄｔ１５遺伝子内の単一塩基多型マーカーを含むチオプリン誘導白血球減少症の発病危険予測用組成物 | |
| Schaefer et al. | Identification of a shared genetic susceptibility locus for coronary heart disease and periodontitis | |
| Cummings et al. | Contribution of the novel inflammatory bowel disease gene IL23R to disease susceptibility and phenotype | |
| Iida et al. | A functional variant in ZNF512B is associated with susceptibility to amyotrophic lateral sclerosis in Japanese | |
| Binder et al. | Common and low frequency variants in MERTK are independently associated with multiple sclerosis susceptibility with discordant association dependent upon HLA-DRB1* 15: 01 status | |
| EP3332031B1 (en) | Snp rs12603226 as a predictive marker for nafld | |
| TW201812125A (zh) | 使用藥物基因體學標記的組合物及方法 | |
| Haylett et al. | Mutations in the parkin gene are a minor cause of Parkinson's disease in the South African population | |
| US10787708B2 (en) | Method of identifying a gene associated with a disease or pathological condition of the disease | |
| Miner et al. | What telomeres teach us about MS | |
| Yu et al. | Single nucleotide polymorphism rs1333049 on chromosome 9p21. 3 is associated with Alzheimer's disease in Han Chinese | |
| Can et al. | Tyrosine kinase-2 gene polymorphisms are associated with ulcerative colitis and Crohn's disease in Turkish Population | |
| Ahani et al. | RB1 gene mutations in Iranian patients with retinoblastoma: report of four novel mutations | |
| WO2015111852A1 (ko) | Nudt15 유전자 내의 단일염기다형성 마커를 포함하는 티오퓨린 유도 백혈구 감소증 발병 위험 예측용 조성물 | |
| JP2022528182A (ja) | 神経膠腫の診断用または予後予測用の組成物、及びそれに係わる情報を提供する方法 | |
| JP5427352B2 (ja) | ヒト体脂肪量と関連する遺伝子多型に基づく肥満発症リスクの判定方法 | |
| KR101497282B1 (ko) | 크론병 감수성 진단용 폴리뉴클레오티드 마커 조성물 | |
| Yan et al. | Case Report: Identification Pathogenic Abnormal Splicing of BBS1 Causing Bardet–Biedl Syndrome Type I (BBS1) due to Missense Mutation | |
| KR101529008B1 (ko) | 크론병 감수성 진단용 폴리뉴클레오티드 마커 조성물 | |
| JP5895317B2 (ja) | 第１０染色体長腕２４領域の一塩基多型に基づく骨・関節疾患の検査方法 | |
| KR101598328B1 (ko) | Dna 복제수 변이를 이용한 강직성 척추염 발병 저위험도 예측용 조성물 및 이를 이용한 예측 방법 | |
| Zhong et al. | Correlation study between ADA and IFN-γ gene polymorphisms and the risk of developing tuberculous pericarditis | |
| KR101545097B1 (ko) | 크론병 감수성 진단용 폴리뉴클레오티드 마커 조성물 | |
| KR102158726B1 (ko) | Itpr3 유전자 업스트림의 유전자간 영역을 포함하는 지연성 허혈 진단용 dna 메틸화 마커 조성물 |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| A621 | Written request for application examination |
Free format text: JAPANESE INTERMEDIATE CODE: A621 Effective date: 20160829 |
|
| A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20170711 |
|
| A601 | Written request for extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A601 Effective date: 20171004 |
|
| A601 | Written request for extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A601 Effective date: 20171211 |
|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20171215 |
|
| TRDD | Decision of grant or rejection written | ||
| A01 | Written decision to grant a patent or to grant a registration (utility model) |
Free format text: JAPANESE INTERMEDIATE CODE: A01 Effective date: 20180508 |
|
| A61 | First payment of annual fees (during grant procedure) |
Free format text: JAPANESE INTERMEDIATE CODE: A61 Effective date: 20180607 |
|
| R150 | Certificate of patent or registration of utility model |
Ref document number: 6353064 Country of ref document: JP Free format text: JAPANESE INTERMEDIATE CODE: R150 |
|
| R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
| R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
| R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
| R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |